Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

BACKGROUND: Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses, pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, Kris, Mark G, Varmus, Harold
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549606/
https://www.ncbi.nlm.nih.gov/pubmed/15737014
http://dx.doi.org/10.1371/journal.pmed.0020073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549606/
https://www.ncbi.nlm.nih.gov/pubmed/15737014
http://dx.doi.org/10.1371/journal.pmed.0020073

Ejemplares similares